Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma

2007 ◽  
Vol 14 (6) ◽  
pp. 539-544 ◽  
Author(s):  
Shuichi Fujioka ◽  
Takeyuki Misawa ◽  
Tomoyoshi Okamoto ◽  
Takeshi Gocho ◽  
Yasuro Futagawa ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Pancreatic Adenocarcinoma ◽  
Carbohydrate Antigen ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen

scholarly journals Diagnostic value of preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 in colorectal cancer

2013 ◽  
Vol 21 (1) ◽  
pp. 1 ◽  
Author(s):  
E. Polat ◽  
U. Duman ◽  
M. Duman ◽  
A.E. Atici ◽  
E. Reyhan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Diagnostic Value ◽  
Carbohydrate Antigen ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen

scholarly journals Clinical Significance of Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 Levels Before Surgery and During Postoperative Follow-Up in Colorectal Cancer

2018 ◽  
Vol 103 (7-8) ◽  
pp. 322-330
Author(s):  
Harunobu Sato ◽  
Yoshikazu Koide ◽  
Miho Shiota ◽  
Hiroshi Takahashi ◽  
Zenichi Morise ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Disease Free Survival ◽  
Carbohydrate Antigen ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen ◽  
Group A ◽  
Serum Cea ◽  
Group B

Objective: Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are the most common colorectal cancer markers. We aimed to identify the appropriate clinical conditions for measuring serum CEA and CA19-9 levels before surgery and during follow-up. Methods: This study included 1275 colorectal cancer patients who were divided into 3 groups according to preoperative CEA levels (group A, ≤5 ng/mL; group B, >5–≤11 ng/mL; group C, >11 ng/mL). Each group was subdivided into 2 groups according to preoperative CA19-9 levels (cutoff level: ≤37 U/mL). Recurrence and survival rates were analyzed. Results: Recurrence rate, disease-free survival after curative surgery, and prognosis were significantly worse in group A and B patients with high CA19-9 levels. At recurrence, CEA levels showed a greater increase in group B and C patients; CA19-9 levels increased in group A patients with high CA19-9 levels. At recurrence, high serum CA19-9 levels were observed in group A patients with high preoperative serum CA19-9 levels, even if the serum CEA level did not increase. Preoperative CA19-9 levels could predict recurrence and prognosis in groups A and B. Conclusion: Periodic CA19-9 determination is useful for monitoring recurrence among group A patients with high CA19-9 levels.

Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer

2017 ◽  
Vol 21 (11) ◽  
pp. 1775-1783 ◽  
Author(s):  
Tobias S. Schiergens ◽  
Bernhard W. Renz ◽  
Simone Reu ◽  
Jens Neumann ◽  
Rami Al-Sayegh ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Prognostic Value ◽  
Carbohydrate Antigen ◽  
Ampullary Cancer ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen

scholarly journals Preoperative Serum Carcinoembryonic Antigen as a Marker for Predicting the Outcome of Three Cancers

2017 ◽  
Vol 9 ◽  
pp. 1179299X1769014 ◽  
Author(s):  
Jingzhu Nan ◽  
Juan Li ◽  
Xiujuan Li ◽  
Guanghong Guo ◽  
Xinyu Wen ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Carcinoembryonic Antigen ◽  
Youden Index ◽  
Rank Test ◽  
Prognostic Information ◽  
Treatment Implementation ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea

Background: Serum levels of carcinoembryonic antigen (CEA) are associated with a variety of tumors. Objective: This study evaluated the prognostic value of pretreatment serum CEA levels in predicting the outcomes of multiple tumors subjected to treatment. Methods: Prior to therapy, serum samples from 71 prostate, 46 breast, 77 gastric, and 31 pancreatic cancer patients were collected to examine serum CEA levels. The cutoff value for CEA was set as determined by the maximum Youden index. The data were analyzed by the Kaplan-Meier curves generated by the log-rank test and Cox multivariate analysis. Results: The overall survival rate for all the patients was 71.11%. The 3-year survival rate of patients with prostate, breast, gastric, and pancreatic cancers was 81.69%, 95.65%, 54.55%, and 51.61%, respectively. The 3-year survival rate showed significant statistical differences between patients with serum CEA levels <2.885 µg/L and those with serum CEA levels ⩾2.885 µg/L ( P < .001). The statistical differences of the 3-year survival rate also existed in the men ( P = .010) or women group ( P < .001), as well as in the 3 different types of cancer, which include breast cancer ( P = .025), gastric cancer ( P = .001), and pancreatic cancer ( P = .047). Conclusions: Serum CEA levels can provide additional prognostic information and may be useful in treatment implementation for patients with breast, gastric, or pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document